1834 Investment Advisors Co. Acquires 482 Shares of Edwards Lifesciences Co. (NYSE:EW)

1834 Investment Advisors Co. increased its holdings in Edwards Lifesciences Co. (NYSE:EWFree Report) by 6.6% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 7,756 shares of the medical research company’s stock after purchasing an additional 482 shares during the period. 1834 Investment Advisors Co.’s holdings in Edwards Lifesciences were worth $741,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in EW. DSM Capital Partners LLC bought a new position in shares of Edwards Lifesciences during the 4th quarter worth approximately $28,000. Turtle Creek Wealth Advisors LLC acquired a new position in Edwards Lifesciences during the fourth quarter worth $34,000. Riverview Trust Co bought a new position in shares of Edwards Lifesciences during the first quarter valued at $34,000. Pingora Partners LLC acquired a new stake in shares of Edwards Lifesciences in the 4th quarter valued at $38,000. Finally, Burkett Financial Services LLC bought a new stake in shares of Edwards Lifesciences in the 4th quarter worth about $46,000. Institutional investors own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Mizuho boosted their price target on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the company a “buy” rating in a research report on Thursday, April 11th. Barclays boosted their target price on Edwards Lifesciences from $100.00 to $101.00 and gave the stock an “overweight” rating in a report on Tuesday, May 7th. Stifel Nicolaus raised their price target on Edwards Lifesciences from $83.00 to $85.00 and gave the company a “hold” rating in a report on Friday, April 26th. The Goldman Sachs Group assumed coverage on Edwards Lifesciences in a research note on Thursday, May 30th. They issued a “buy” rating and a $107.00 price objective on the stock. Finally, Deutsche Bank Aktiengesellschaft upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and raised their target price for the company from $86.00 to $103.00 in a research note on Tuesday, May 14th. One analyst has rated the stock with a sell rating, five have issued a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $95.18.

Get Our Latest Research Report on EW

Edwards Lifesciences Trading Up 1.4 %

Shares of NYSE:EW traded up $1.24 during midday trading on Friday, hitting $92.32. The company had a trading volume of 1,515,155 shares, compared to its average volume of 2,959,638. The company has a current ratio of 3.75, a quick ratio of 2.67 and a debt-to-equity ratio of 0.08. Edwards Lifesciences Co. has a 12 month low of $60.57 and a 12 month high of $96.12. The firm has a fifty day simple moving average of $88.22 and a 200 day simple moving average of $85.76. The stock has a market cap of $55.63 billion, a price-to-earnings ratio of 39.79, a PEG ratio of 3.33 and a beta of 1.11.

Edwards Lifesciences (NYSE:EWGet Free Report) last issued its earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. The firm had revenue of $1.60 billion for the quarter, compared to analysts’ expectations of $1.58 billion. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. On average, analysts predict that Edwards Lifesciences Co. will post 2.77 EPS for the current year.

Insiders Place Their Bets

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $87.54, for a total value of $437,700.00. Following the completion of the sale, the vice president now owns 46,936 shares in the company, valued at approximately $4,108,777.44. The transaction was disclosed in a filing with the SEC, which is available through this link. In related news, CEO Bernard J. Zovighian purchased 580 shares of the business’s stock in a transaction on Monday, May 6th. The shares were purchased at an average price of $85.74 per share, with a total value of $49,729.20. Following the completion of the purchase, the chief executive officer now owns 3,268 shares in the company, valued at approximately $280,198.32. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $87.54, for a total transaction of $437,700.00. Following the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $4,108,777.44. The disclosure for this sale can be found here. Over the last three months, insiders have sold 90,499 shares of company stock worth $7,866,511. Company insiders own 1.27% of the company’s stock.

About Edwards Lifesciences

(Free Report)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

See Also

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EWFree Report).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.